Evotec SE (EVO) announced progress within the strategic partnership with Bristol Myers Squibb. Evotec received a $25 million payment to progress further research. A first programme, EVT8683, was in-licensed by Bristol Myers Squibb in September 2021 as BMS-986419. A Phase II study for BMS-986419 is scheduled to commence in 2024.
The companies entered their strategic neuroscience collaboration in December 2016. In March 2023, the companies extended and expanded the partnership for an additional 8 years.
Cord Dohrmann, Chief Scientific Officer of Evotec, said: "As the first asset from our neuroscience partnership with Bristol Myers Squibb is moving towards a Phase II study, our partnership is still growing in the drug discovery phase as well."
For More Such Health News, visit rttnews.com.
For comments and feedback: editorial@rttnews.com